Antonio Valdes Dapena, MD
Family Medicine · Bowling Green, VANPI 1942292511
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $314 and has fallen 83.3% since, to $52 in 2024.
Across 41 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$154
- Novo Nordisk$145
- Pfizer$88
- AbbVie$84
- Astellas Pharma US Inc$54
- Boehringer Ingelheim$37
- plus $163 from 8 others
What the payments were for
- Food & beverage$726100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 7 | $154 |
| Novo Nordisk | 8 | $145 |
| Pfizer | 5 | $88 |
| AbbVie | 5 | $84 |
| Astellas Pharma US Inc | 3 | $54 |
| Boehringer Ingelheim | 2 | $37 |
| GSK | 2 | $33 |
| Johnson & Johnson | 2 | $29 |
| Mylan Specialty L.p. | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$726 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 53 | $61,999 |
| JardianceEmpagliflozin | 30 | $43,144 |
| OzempicSemaglutide | 24 | $36,369 |
| JanuviaSitagliptin Phosphate | 13 | $15,236 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,900 |
| XareltoRivaroxaban | 12 | $12,353 |
| MyrbetriqMirabegron | 12 | $9,277 |
| LinzessLinaclotide | 16 | $9,050 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $8,170 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,374 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $4,764 |
| LantusInsulin Glargine,hum.Rec.Anlog | 12 | $3,547 |
| Atorvastatin Calcium | 378 | $2,833 |
| Esomeprazole Magnesium | 16 | $2,062 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $1,913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $61,99953 claims |
| Boehringer IngelheimJardiance | $37 | $43,14430 claims |
| Novo NordiskOzempic | $145 | $36,36924 claims |
| GSKTrelegy Ellipta | $33 | $12,90012 claims |
| Johnson & JohnsonXarelto | $29 | $12,35312 claims |
| AbbVieLinzess, Synthroid | $84 | $10,26929 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $9,27712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Bowling Green
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.